Posted by Michael Wonder on 26 Aug 2022
Incyte announces FDA approval of Pemazyre (pemigatinib) as the first and only targeted treatment for myeloid/lymphoid neoplasms with FGFR1 rearrangement
26 August 2022 - Pemazyre is the only FGFR inhibitor with multiple indications
Incyte today announced that the US FDA has approved Pemazyre (pemigatinib), a selective fibroblast growth factor receptor inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
